PMID- 21503696
OWN - NLM
STAT- MEDLINE
DCOM- 20110830
LR  - 20211020
IS  - 1534-6307 (Electronic)
IS  - 1523-3774 (Linking)
VI  - 13
IP  - 3
DP  - 2011 Jun
TI  - Mechanisms of action of intravenous immunoglobulin in inflammatory muscle 
      disease.
PG  - 192-8
LID - 10.1007/s11926-011-0171-0 [doi]
AB  - Intravenous immunoglobulin (IVIG) is a unique immune-modulating therapy that has 
      a wide range of effects on the immune system at multiple levels. This allows it 
      to be used successfully in a variety of immune-mediated, systemic, and 
      neurological disorders, including the inflammatory myopathies. It is likely that 
      the specific action of IVIG varies depending on the underlying pathogenesis of a 
      given disease. In dermatomyositis (DM), IVIG has been shown to diminish the 
      activity of complement and deposition of membrane attack complex on capillaries 
      and muscle fibers, the expression of adhesion molecules, and cytokine production. 
      IVIG also appears to modify gene expression in the muscle of DM patients. The 
      mechanism by which IVIG affects muscle in polymyositis and inclusion body 
      myositis has not been well-studied. However, it may work via suppression of 
      T-cell activation (including cytotoxic T cells) and migration into muscle tissue 
      and alterations in cytokine production. IVIG generally yields the greatest 
      therapeutic benefit in DM and is often of marginal utility in inclusion body 
      myositis. It is generally considered as second-line or adjunctive therapy in the 
      inflammatory myopathies.
FAU - Quick, Adam
AU  - Quick A
AD  - Ohio State University School of Medicine, Columbus, OH, USA. adam.quick@osumc.edu
FAU - Tandan, Rup
AU  - Tandan R
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Rheumatol Rep
JT  - Current rheumatology reports
JID - 100888970
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Immunologic Factors)
SB  - IM
MH  - Dermatomyositis/genetics/immunology/therapy
MH  - Gene Expression Regulation/drug effects
MH  - Humans
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - Immunologic Factors/*therapeutic use
MH  - Lymphocyte Activation/drug effects
MH  - Muscle, Skeletal/drug effects/immunology
MH  - Myositis/genetics/immunology/*therapy
MH  - Myositis, Inclusion Body/genetics/immunology/therapy
MH  - Polymyositis/genetics/immunology/therapy
MH  - T-Lymphocytes/drug effects/immunology
EDAT- 2011/04/20 06:00
MHDA- 2011/08/31 06:00
CRDT- 2011/04/20 06:00
PHST- 2011/04/20 06:00 [entrez]
PHST- 2011/04/20 06:00 [pubmed]
PHST- 2011/08/31 06:00 [medline]
AID - 10.1007/s11926-011-0171-0 [doi]
PST - ppublish
SO  - Curr Rheumatol Rep. 2011 Jun;13(3):192-8. doi: 10.1007/s11926-011-0171-0.